Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program
Repeated treatment with oral esketamine is effective in improving depressive symptom severity in highly treatment-resistant depressive patients. It is safe, well tolerated, and patient-friendly. Considering the level of treatment resistance, outcomes were in the range of studies investigating other routes of (es)ketamine administration.
Authors
- Jolien K. E. Veraart (ORCID: https://orcid.org/0000-0002-9075-4804)
- Jeanine Kamphuis
- Robert A. Schoevers (ORCID: https://orcid.org/0000-0003-0760-9866)
- Annemarie van der Meij
- Sanne Y. Smith-Apeldoorn (ORCID: https://orcid.org/0000-0002-9133-262X)
- Jan Spijker (ORCID: https://orcid.org/0000-0003-1480-9647)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Parnassia Groep (NL)
- Pro Persona (NL)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1177/02698811251332831
- Citations
- 2
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 2.79